References
Gandjour A. Comment on “The cost effectiveness of high-dose versus conventional haemodialysis: a systematic review”. Appl Health Econ Health Policy. 2016:1–2. doi:10.1007/s40258-016-0273-y.
Laplante S, Liu FX, Culleton B, et al. The cost effectiveness of high-dose versus conventional haemodialysis: a systematic review. Appl Health Econ Health Policy. 2016;14(2):185–93.
Blagg CR, Kjellstrand CM, Ting GO, et al. Comparison of survival between short-daily hemodialysis and conventional hemodialysis using the standardized mortality ratio. Hemodial Int. 2006;10:371–4.
Nesrallah GE, Lindsay RM, Cuerden MS, et al. Intensive hemodialysis associates with improved survival compared with conventional hemodialysis. J Am Soc Nephrol. 2012;23:696–705.
Marshall MR, Hawley CM, Kerr PG, et al. Home hemodialysis and mortality risk in Australian and New Zealand populations. Am J Kidney Dis. 2011;58:782–93.
Weinhandl ED, Liu J, Gilbertson DT, et al. Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. J Am Soc Nephrol. 2012;23:895–904.
Liu FX, Treharne C, Arici M, et al. High-dose hemodialysis versus conventional in- hemodialysis: a cost-utility analysis from a UK payer perspective. Value Health. 2015;18:17–24.
Johansen KL, Zhang R, Huang Y, et al. Survival and hospitalization among patients using nocturnal and short daily compared to conventional hemodialysis: a USRDS study. Kidney Int. 2009;76:984–90.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This reply was funded by Baxter Healthcare Corporation.
Conflict of interest
S. Laplante, A. Bernardo, F. X. Liu, and B. Culleton are employees of Baxter Healthcare Corporation. D. King and P. Hudson received consultancy fees from Baxter Healthcare Corporation.
Additional information
This reply refers to the commentary article available at doi:10.1007/s40258-016-0273-y
Rights and permissions
About this article
Cite this article
Laplante, S., Liu, F.X., Culleton, B. et al. Authors’ Reply to Gandjour “The Cost Effectiveness of High-Dose Versus Conventional Haemodialysis: A Systematic Review”. Appl Health Econ Health Policy 14, 731–732 (2016). https://doi.org/10.1007/s40258-016-0284-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40258-016-0284-8